Eflapegrastim
Eflapegrastim
Eflapegrastim (pronounced as ef-la-peg-ras-tim) is a biopharmaceutical drug used to stimulate the production of neutrophils, a type of white blood cell, in patients undergoing chemotherapy.
Etymology
The term "Eflapegrastim" is derived from the prefix "Ef-", which is an abbreviation for "effect", and "la", which stands for "long-acting". "Peg" is short for "pegylated", a process that extends the drug's half-life in the body. "Grastim" is a common suffix for drugs that stimulate the production of granulocytes, a category of white blood cells that includes neutrophils.
Usage
Eflapegrastim is used to reduce the chance of infection due to a low white blood cell count, known as neutropenia, in patients who are receiving strong chemotherapy drugs. It works by stimulating the growth of neutrophils in the bone marrow, thereby increasing their numbers in the bloodstream.
Related Terms
- Neutropenia: A condition characterized by an abnormally low number of neutrophils.
- Chemotherapy: A type of cancer treatment that uses drugs to destroy cancer cells.
- Biopharmaceutical: A type of drug produced using biotechnology.
- Neutrophils: A type of white blood cell that is one of the body's mechanisms for fighting off infections.
- Granulocytes: A category of white blood cells that includes neutrophils.
- Pegylation: A process that extends the drug's half-life in the body.
External links
- Medical encyclopedia article on Eflapegrastim
- Wikipedia's article - Eflapegrastim
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski